CXCR1+ tumor cells represented, as expected, a small percentage of cells (range 0.1–9.2%) in baseline samples [4] and were decreased at day 21 in 7/13 evaluable patients (Fig. 3b). This evidence concerns the gene CXCR1 and neoplasm.